These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14968337)

  • 21. Repetitive application of remote ischemic conditioning (RIC) in patients with peripheral arterial occlusive disease (PAOD) as a non-invasive treatment option: study protocol for a randomised controlled clinical trial.
    Hummitzsch L; Voelckers L; Rusch M; Cremer J; Albrecht M; Rusch R; Berndt R
    BMC Cardiovasc Disord; 2022 Aug; 22(1):353. PubMed ID: 35927627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.
    Mondillo S; Ballo P; Barbati R; Guerrini F; Ammaturo T; Agricola E; Pastore M; Borrello F; Belcastro M; Picchi A; Nami R
    Am J Med; 2003 Apr; 114(5):359-64. PubMed ID: 12714124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
    van Wissen S; Smilde TJ; de Groot E; Hutten BA; Kastelein JJ; Stalenhoef AF
    Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):451-5. PubMed ID: 14671468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
    Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
    Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
    Semb AG; Holme I; Kvien TK; Pedersen TR
    Rheumatology (Oxford); 2011 Feb; 50(2):324-9. PubMed ID: 20884656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D
    Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
    Alemao E; Yin D; Sintonen H; Salomaa V; Jousilahti P
    Am J Cardiovasc Drugs; 2006; 6(5):349-55. PubMed ID: 17083270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
    Farnier M; Portal JJ; Maigret P
    J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):27-32. PubMed ID: 10687671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
    van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
    J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC;
    Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study.
    Grodzińska L; Starzyk D; Bieroń K; Goszcz A; Korbut R
    Basic Clin Pharmacol Toxicol; 2005 Jun; 96(6):413-9. PubMed ID: 15910404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):85-6. PubMed ID: 15727720
    [No Abstract]   [Full Text] [Related]  

  • 39. Hemostatic effects of atorvastatin versus simvastatin.
    Kadikoylu G; Yukselen V; Yavasoglu I; Bolaman Z
    Ann Pharmacother; 2003 Apr; 37(4):478-84. PubMed ID: 12659599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.
    Wu SC; Shiang JC; Lin SL; Wu TL; Huang WC; Chiou KR; Liu CP
    Heart Vessels; 2005 Sep; 20(5):217-23. PubMed ID: 16160904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.